吴知桂，女，1987年生，博士，副教授。2018年毕业于四川大学，西南医科大学药学院硕士研究生导师，哈佛医学院丹娜法伯癌症研究中心访问学者，现工作于西南医科大学附属医院药学部，主要承担临床药学相关的临床、科研和教学工作。四川省抗癌协会抗癌药物专委会委员，四川省抗癌协会肿瘤临床药学专委会委员、泸州市药学会委员，泸州市药学会临床药学专委会委员。主持国家自然科学基金、四川省科技厅、泸州市以及校级等科研项目，指导大学生创新创业项目多项。

研究方向：（1）肿瘤免疫机制与治疗策略研究；（2）抗肿瘤药物的临床综合评价与合理用药研究

主要发表论文：

1. Liu Yang, Xingyue Wang, Shurong Wang, Jing Shen, Yaling Li, Shengli Wan, Zhangang Xiao, Zhigui Wu*,Targeting lipid metabolism in regulatory T cells for enhancing cancer immunotherapy, Biochimica et Biophysica Acta (BBA)-Reviews on Cancer,2025 Jan 10;1880(2):189259.

2. Junxin Li, Jing Shen, Yueshui Zhao, Fukuan Du, Mingxing Li, Xu Wu, Yu Chen, Shurong Wang, Zhangang Xiao, Zhigui Wu*. Role of miR 181a 5p in cancer, International Journal of Oncology, 2023, 63(4): 1-18

3. Yao Liu, Xuemei Sun, Xinpei Hu, Yitian Xu, Teng Li, Zhigui Wu*. Pharmacological properties and underlying mechanisms of aurantio obtusin,. Experimental and Therapeutic Medicine, 2023, 26(2): 1-8.

4. Zhigui Wu, Yuan Li, Rong Li, Xuemei Sun, Tao Chen, Yongqi Yu, Yue Shi, Hongli Luo,. Secular trend analysis of antibiotic utilisation in some hospitals in Southern Sichuan from 2010 to 2020[J]. Scientific Reports, 2023, 13(1): 8111.

5. Zou T, Gu L, Yang L, Wei J, Zhao Y, Shen J, Li M, Wu X, Du F, Chen Y, Ye Y, Xiao Z, Zhigui Wu*. Alpha-solanine anti-tumor effects in non-small cell lung cancer through regulating the energy metabolism pathway. Recent Pat Anticancer Drug Discov. 2022;17(4):396-409.

6. Kui Liao, L Gong, Yi Yang, Y He, F Wang, Y Huang, Zhigui Wu*,A comprehensive review of research progress in Chinese medicines for primary liver cancer treatment[J]. Tradit. Med. Res, 2022, 7(2): 10.

7. Zou T, Huang Y, Hu Y, Wu M, Zhao Y, Du F, Li M, Wu X, Ji H, Kaboli PJ, Wang S, Xiao Z, Zhigui Wu*. The anti-tumor mechanism and target of triptolide based on network pharmacology and molecular docking. Recent Pat Anticancer Drug Discov. 2021;16(3):426-435.

8. Zhigui Wu, Gu L, Si Y, Yin W, Zhao M, Zhang T, Chen M. Macrovascular protecting effects of Berberine through anti-inflammation and intervention of BKCa in type 2 diabetes mellitus rats. Endocr Metab Immune Disord Drug Targets. 2021;21(7):1270-1281.

9. Zhigui Wu, Yin W, Sun M, Si Y, Wu X, Chen M. BKCa mediates dysfunction in high glucose induced mesangial cell injury via TGF-β1/Smad2/3 signaling pathways. Int J Endocrinol. 2020;2020:3260728.

单位：西南医科大学药学院临床药学教研室

通讯地址：泸州市江阳区忠山路西南医科大学附属医院药学部

E-mail:zhiguiwu18@126.com